Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$79.23

-0.055 (-0.07%)

, ABT

Abbott

$38.10

-0.14 (-0.37%)

11:31
12/22/16
12/22
11:31
12/22/16
11:31

U.S. poised to approve Abbott deal to buy St. Jude Medical, Reuters says

STJ

Acquired by ABT

$79.23

-0.055 (-0.07%)

ABT

Abbott

$38.10

-0.14 (-0.37%)

  • 25

    Jan

  • 21

    Feb

STJ Acquired by ABT
$79.23

-0.055 (-0.07%)

08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
ABT Abbott
$38.10

-0.14 (-0.37%)

10/20/16
LEER
10/20/16
NO CHANGE
Target $45
LEER
Market Perform
Abbott selloff overdone as long-term fundamentals remain intact, says Leerink
Leerink analyst Danielle Antalffy believes the selloff in Abbott's shares is overdone, as long-term fundamentals remain intact. With another "solid" quarter in hand, despite a weaker than expected Nutritionals performance, the analyst believes the company seems to remain "solidly" on track to deliver improving operational results in 2017, after a year in which it is reshaping the portfolio by acquiring higher-growth assets and shedding slower, lower-margin businesses. Antalffy reiterates a Market Perform rating on the stock but lowered her price target on the shares to $45 from $48.
10/25/16
RBCM
10/25/16
NO CHANGE
RBCM
Abbott should be bought on recent weakness, says RBC Capital
After Abbott reported slightly stronger than expected Q3 results, RBC Capital analyst Glenn Novarro predicts that the company's 2016 EPS will come in at $2.63, excluding its acquisition of Alere. The analyst thinks that Abbott's EPs can rise to $2.93 in 2018, excluding the Alere deal, driven by lower interest costs and higher synergies. He says that recent weakness in the stock has been caused by issues that are "either transient or can be offset." The analyst keeps a $48 price target and Outperform rating on the stock.
12/08/16
ADAM
12/08/16
NO CHANGE
Target $52
ADAM
Buy
Legal rights in favor of Alere in buyout fight, says Canaccord
Canaccord analyst Mark Massaro noted Abbot (ABT) filed a lawsuit to terminate its acquisition of Alere (ALR), which sent the latter's stock below where it was prior to the original deal being struck. The analyst said the legal jurisdiction is in Delaware, which heavily favors Alere, who said they will take whatever actions are necessary to make Abbott complete the transaction. Alere is confident the deal will be completed at the agreed upon terms, with the company in a good position to have its Arriva Medical business reimbursement restored by the CMS, said Massaro, who raised his price target to $52 from $50 and reiterated his Buy rating on Alere shares.
12/19/16
12/19/16
UPGRADE
Target $84

Outperform
Dexcom upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Steven Lichtman upgraded Dexcom (DXCM) to Outperform from Perform, with an $84 price target, given valuation reflecting competitive concerns and big long-term opportunities in place. While new competition in the U.S. is expected from Medtronic (MDT) and likely Abbott (ABT) and Senseonics (SENS) in 2017, the analyst believes the CGM market remains underpenetrated in Type 1 patients, a dosing claim is expected early 2017, international reimbursement should be a growing tailwind and 2018 brings new growth drivers with expected launch of Dexcom's next-generation G6 and potential Medicare expansion.

TODAY'S FREE FLY STORIES

DE

Deere

$139.23

2.31 (1.69%)

20:25
11/21/17
11/21
20:25
11/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

PCRX

Pacira

$42.65

0.45 (1.07%)

19:24
11/21/17
11/21
19:24
11/21/17
19:24
Recommendations
Pacira analyst commentary at BMO Capital »

October Symphony data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

  • 06

    Apr

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

19:00
11/21/17
11/21
19:00
11/21/17
19:00
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

CNX

Consol

$16.27

0.23 (1.43%)

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:52
11/21/17
11/21
18:52
11/21/17
18:52
Recommendations
TiVo, Comcast analyst commentary at JPMorgan »

ITC ruling a…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$25.35

-2.86 (-10.14%)

18:48
11/21/17
11/21
18:48
11/21/17
18:48
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Glaukos selloff due to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$103.00

0.25 (0.24%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:31
11/21/17
11/21
18:31
11/21/17
18:31
Periodicals
Hulu sued for failure to offer audio service for blind subscribers, NY Post says »

Advocacy groups are suing…

DIS

Disney

$103.00

0.25 (0.24%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

TWX

Time Warner

$89.56

1.85 (2.11%)

FOX

21st Century Fox

$30.10

0.2 (0.67%)

FOXA

21st Century Fox

$30.88

0.22 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.29

0.37 (0.69%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Magna announces two share repurchase programs »

Magna International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

PTLA

Portola Pharmaceuticals

$50.80

1.29 (2.61%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Portola: FDA extends review period for PAS for Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

PBMD

Prima BioMed

$1.65

-0.03 (-1.79%)

18:09
11/21/17
11/21
18:09
11/21/17
18:09
Hot Stocks
Prima BioMed secures European patent grant for lead product IMP321 in cancer »

Prima BioMed announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$36.70

0.39 (1.07%)

18:06
11/21/17
11/21
18:06
11/21/17
18:06
Earnings
Copart reports Q1 non-GAAP EPS 33c, consensus 27c »

Reports Q1 revenue 419.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 19

    Dec

PCTY

Paylocity

$47.79

-0.64 (-1.32%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
Paylocity chairman sells 736,845 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDC

M.D.C. Holdings

$35.10

0.91 (2.66%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
M.D.C. Holdings declares special 8% stock dividend »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

, BBOX

Black Box

$4.15

0.55 (15.28%)

17:59
11/21/17
11/21
17:59
11/21/17
17:59
Hot Stocks
Breaking Hot Stocks news story on PDF Solutions, Black Box »

PDF Solutions to replace…

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:58
11/21/17
11/21
17:58
11/21/17
17:58
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees pressure on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

17:57
11/21/17
11/21
17:57
11/21/17
17:57
Hot Stocks
Breaking Hot Stocks news story on CONSOL Energy, Iconix Brand »

CONSOL Energy to replace…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. says returned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TMQ

Trilogy Metals

$0.92

-0.0211 (-2.25%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Syndicate
Breaking Syndicate news story on Trilogy Metals »

Trilogy Metals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

17:50
11/21/17
11/21
17:50
11/21/17
17:50
Initiation
Terreno Realty initiated at National Securities »

Terreno Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HPQ

HP Inc.

$22.47

0.355 (1.61%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Hot Stocks
HP Inc.: 'Stay tuned' for news on metal 3D printing »

Says plans to introduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

THC

Tenet

$13.34

0.17 (1.29%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
Tenet initiated at William Blair »

Tenet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$43.85

0.65 (1.50%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
LifePoint initiated at William Blair »

LifePoint initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LHCG

LHC Group

$67.98

1.46 (2.19%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
LHC Group initiated at William Blair »

LHC Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

HLS

HealthSouth

$48.46

0.85 (1.79%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HealthSouth initiated at William Blair »

HealthSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$75.89

1.28 (1.72%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HCA Healthcare initiated at William Blair »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMED

Amedisys

$54.97

2.29 (4.35%)

17:45
11/21/17
11/21
17:45
11/21/17
17:45
Initiation
Amedisys initiated at William Blair »

Amedisys initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.